A new molecular target in Alzheimer's disease: early evidence from animal models

News summary

ScienceDaily reported that blocking a lesser-known protein pathway reduced Alzheimer's-like damage in mice. The Cell Reports Medicine paper found increased aggregated, phosphorylated GRK2 in Alzheimer's models and in human brain samples from people with dementia likely due to Alzheimer's disease. Small molecules that restored functional GRK2 signaling countered several pathological features and neuronal loss in animal models.

Aggregated phospho-S670-GRK2 was linked to mitochondrial dysfunction and increased amyloid. Manipulating this pathway with small molecules reduced several neuropathological features and improved survival in mice.

The study identifies a new research target for Alzheimer's disease, but there is no evidence yet that the compound is safe or effective in people. The gap between success in mouse models and a useful human therapy can be substantial.

Therapeutic results came mainly from animal and laboratory models. Detecting aggregated GRK2 in human tissue does not establish that targeting the pathway will be effective in patients.